Paul Elliot Mann Sells 83,759 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Elliot Mann sold 83,759 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $7.76, for a total value of $649,969.84. Following the completion of the sale, the chief executive officer owned 9,579,845 shares in the company, valued at $74,339,597.20. This represents a 0.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paul Elliot Mann also recently made the following trade(s):

• On Tuesday, June 2nd, Paul Elliot Mann sold 83,758 shares of ASP Isotopes stock. The shares were sold at an average price of $8.29, for a total value of $694,353.82.

ASP Isotopes Stock Up 5.6%

NASDAQ ASPI opened at $7.97 on Friday. The stock has a 50 day moving average price of $5.50 and a 200-day moving average price of $5.87. ASP Isotopes Inc. has a one year low of $3.92 and a one year high of $14.49. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.37 and a current ratio of 4.39. The company has a market capitalization of $1.00 billion, a P/E ratio of -3.83 and a beta of 3.42.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.06. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%. The company had revenue of $8.36 million for the quarter, compared to analysts’ expectations of $3.68 million.

Institutional Investors Weigh In On ASP Isotopes

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP purchased a new stake in ASP Isotopes in the 3rd quarter valued at about $34,000. BNP Paribas Financial Markets increased its position in shares of ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after acquiring an additional 2,548 shares during the period. State of Wyoming bought a new stake in shares of ASP Isotopes during the first quarter valued at approximately $29,000. Close Asset Management Ltd purchased a new stake in shares of ASP Isotopes in the third quarter valued at approximately $72,000. Finally, Legal & General Group Plc boosted its holdings in shares of ASP Isotopes by 30.4% in the third quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after purchasing an additional 1,953 shares during the period. Institutional investors own 16.80% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 price target on shares of ASP Isotopes in a research report on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.